REZITENT ARTERIAL GIPERTENZIYA BILAN OG'RIGAN BEMORLARDA TORASEMIDNING KOMBINIRLANGAN ANTIHIPERTENZIV TERAPIYADA ANTIGIPERTENZIV SAMARADORLIGI
##article.subject##:
antigipertenziv terapiya, rezistent arterial gipertenziya, organoprotektsiya, torasemid##article.abstract##
Tadqiqot maqsadi: Rezistent arterial gipertenziyaning kombinatsiyalangan 3 oylik antigipertenziv tarkibida torasemidni antigipertenziv va vazoprotektiv samaradorligini oʼrganish.
Materiallar va usullar: Tadqiqotda respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazida ambulator davolanayotgan 30 nafar rezistent arterial gipertoniya kasalligi bilan ogʼrigan bemor ishtirok etdi. Har bir bemorning xavf omillari va nishon aʼzolarning shikastlanishini aniqlash uchun tekshirildi. Bayonnomaga muvofiq quyidagi tekshiruvlar oʼtkazildi: klinik koʼrik, ambulator arterial bosimi monitoringi (ААBM), exokardiografiya (ExoKG), braxiotsefal arteriyalarning ultratovush tekshiruvi (BCАUTT), applanatsion tonometriyasi, qonning lipid spektrini aniqlash, qon tarkibida elektrolitlar miqdori, glyukoza, kreatinin, qon siydik kislotasi, siydikda mikroalbuminuriya miqdori.
Natijalar: Umuman olganda, torasemidni o'z ichiga olgan 3 oylik kombinatsiyalangan AGT yuqori antihipertenziv samaradorlikni ko'rsatdi. SAB-19,0±4,5%, DAB-15,3±6,1%, O’AB 17,1±4,7% ga ishochli pasayishi qayd etildi.
Xulosa: Rezistent arterial gipertenziyaning torasemid bilan kombinatsiyalangan antigipertenziv terapiyaning yuqori antigipertenziv samaradorligini koʼrsatdi, bir vaqtning oʼzida 80% bemorlarda sistolik arterial bosimi (SАB) va diastolik arterial bosimning (DАB) maqsadli darajasiga erishish va sutkalik arterial bosim profili koʼrsatkichlariga ijobiy taʼsir koʼrsatdi.
Библиографические ссылки
STEPS: prevalence of risk factors for noncommunicable diseases in the Republic of Uzbekistan, 2019. Web Appendix 1. Fact sheet. Copenhagen: WHO Regional Office for Europe; 2022.
Mancia G., Kreutz R., et al.. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26. PMID: 37345492
Евдокимова А.Г., Евдокимов В.В., Аркадьева Г.В., Коваленко Е.В., Теблоев К.И. Антигипертензивные и органопротективные эффекты торасемида. Журнал Сердечная Недостаточность. 2016;17 (2):130–136
Friedel H, Buckley M. Torasemide A review of its pharmacological properties and therapeutic potential. Drugs 1991; 41 (1): 81–103.
Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
Dunn CJ, Fitton A, Broglen RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49 (1):121–42.
Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J. Torasemide inhibits angiotensin II-induced vasoconstriction and intractllular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34 (1):138–43.
Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ и ВНОК. Системные гипертензии. 2010;3:5–26
Гиляревский С.Р., Кузьмина И.М., Келехсаев Х.Р. Применение торасемида при лечении артериальной гипертонии: абсолютные и относительные показания в реальной клинической практике. Сердце. 2011;10 (5):278–81
Теблоев К.И., Евдокимова А.Г., Ложкина М.В., Евдокимов В.В. Современные возможности оптимизации лечения больных АГ и ХСН при применении торасемида. рмЖ. 2013; 27: 1388
Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025–30.
Luft FC. Torasemide in the treatment of arterial hypertension. J Cardiovasc Pharmacol 1993; 22 (Suppl. 3): S32–9. 52. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
